| abstract |
The present invention relates to efflux inhibitor compositions and methods of using these agents to treat conditions in which the activity of efflux transporters such as breast cancer resistance protein (BCRP) and P-glycoprotein (P-GP) Inhibition of therapeutic agents to target tissues (eg, brain, spinal cord, nerves, cerebrospinal fluid, testis, eyeball, retina, inner ear, placenta, breast, liver, biliary tract, kidney, intestine, lung, adrenal cortex, endometrium, hematopoietic cells and and/or stem cells). |